{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T11:39:43Z","timestamp":1788089983461,"version":"build-2803163510"},"reference-count":14,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Background: Bortezomib, a proteasome inhibitor used in multiple myeloma (MM), is associated with several adverse effects, most notably peripheral neuropathy. Ototoxicity, however, remains a rare and underrecognized complication. Case presentation: We report the case of a 74-year-old man with MM who developed sudden unilateral sensorineural hearing loss following subcutaneous bortezomib administration. Audiometry confirmed severe right-sided hearing loss. MRI of the internal auditory canal was normal. Given the absence of other ototoxic agents, bortezomib was identified as the likely causative drug. The patient was treated with intratympanic dexamethasone injections, achieving partial hearing recovery. Subsequent chemotherapy re-exposure triggered another hearing decline, which again improved after repeated intratympanic treatment. Conclusions: Bortezomib-related ototoxicity is a rare but potentially reversible adverse event. This case suggests that early intratympanic corticosteroid therapy may mitigate cochlear injury, allowing continuation of chemotherapy for patients responding well to bortezomib.<\/jats:p>","DOI":"10.3390\/hematolrep18010009","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T08:42:58Z","timestamp":1767688978000},"page":"9","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bortezomib-Induced Sensorineural Hearing Loss May Be Reversible with Intratympanic Dexamethasone"],"prefix":"10.3390","volume":"18","author":[{"given":"Natalia","family":"Pel\u00e1ez Casillas","sequence":"first","affiliation":[{"name":"Servicio de Otorrinolaringolog\u00eda, Hospital Universitario Puerta de Hierro Majadahonda, Deparmento de Cirug\u00eda, Facultad de Medicina, Universidad Aut\u00f3noma de Madrid, IDIPHISA, 28222 Majadahonda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Maria","family":"Verdaguer Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Servicio Otorrinolaringolog\u00eda, Hospital Universitario HM Madrid R\u00edo, 28005 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rodr\u00edguez Valiente","sequence":"additional","affiliation":[{"name":"Servicio de Otorrinolaringolog\u00eda, Hospital Universitario Puerta de Hierro Majadahonda, Deparmento de Cirug\u00eda, Facultad de Medicina, Universidad Aut\u00f3noma de Madrid, IDIPHISA, 28222 Majadahonda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Romera Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Servicio Hematolog\u00eda, Hospital Universitario Puerta de Hierro Majadahonda, 28222 Majadahonda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2747-2991","authenticated-orcid":false,"given":"Jose Ram\u00f3n","family":"Garc\u00eda Berrocal","sequence":"additional","affiliation":[{"name":"Servicio de Otorrinolaringolog\u00eda, Hospital Universitario Puerta de Hierro Majadahonda, Deparmento de Cirug\u00eda, Facultad de Medicina, Universidad Aut\u00f3noma de Madrid, IDIPHISA, 28222 Majadahonda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"Pawlyn","year":"2021","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and Management of Multiple Myeloma: A Review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3892\/ijmm.2025.5510","article-title":"Inhibitors of the ubiquitin-proteasome system rescue cellular levels and ion transport function of pathogenic pendrin","volume":"55","author":"Bernardinelli","year":"2025","journal-title":"Int. J. Mol. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1007\/s00405-021-07234-1","article-title":"Relation between auditory difficulties and bortezomib-induced peripheral neuropathy in multiple myeloma: A single-center cross-sectional study","volume":"279","author":"Giraudet","year":"2022","journal-title":"Eur. Arch. Oto-Rhino-Laryngol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.bbrc.2014.11.070","article-title":"Proteasome inhibitors induce auditory hair cell death through peroxisome dysfunction","volume":"456","author":"Lee","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/sj.leu.2403723","article-title":"Severe irreversible bilateral hearing loss after bortezomib (VELCADE) therapy in a multiple myeloma (MM) patient","volume":"19","author":"Engelhardt","year":"2005","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1159\/000539453","article-title":"Hearing Loss in a Patient with Waldenstr\u00f6m Macroglobulinemia Receiving Bortezomib","volume":"17","author":"Fitzsimons","year":"2024","journal-title":"Case Rep. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4103\/0019-509X.200675","article-title":"Sensorineural deafness: An uncommon irreversible adverse effect of bortezomib","volume":"53","author":"Anoop","year":"2016","journal-title":"Indian J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/02841860701558823","article-title":"Deafness associated with the use of bortezomib in multiple myeloma","volume":"47","author":"Chim","year":"2008","journal-title":"Acta Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/sj.bjp.0707405","article-title":"The anticancer drug cisplatin induces an intrinsic apoptotic pathway inside the inner ear","volume":"152","author":"Nevado","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0009-9236(99)70054-8","article-title":"Effect of Dexamethasone on Reactive Oxygen Species Generation by Leukocytes and Plasma Interleukin-10 Concentrations: A Pharmacodynamic Study","volume":"66","author":"Dandona","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/MAO.0b013e3182255933","article-title":"Intratympanic versus intravenous delivery of dexamethasone and dexamethasone sodium phosphate to cochlear perilymph","volume":"32","author":"Bird","year":"2011","journal-title":"Otol. Neurotol."}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/1\/9\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T09:29:00Z","timestamp":1767691740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/1\/9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["hematolrep18010009"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep18010009","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]}}}